INMD Quote, Financials, Valuation and Earnings

Accuray, Inc. has a net margin of 26.02% compared to InMode Ltd.'s net margin of -13.47%. InMode Ltd.'s return on equity of 14.27% beat Accuray, Inc.'s return on equity of -60.6%.

InMode Ltd. has a consensus price target of $16.80, signalling upside risk potential of 11.3%. On the other hand Accuray, Inc. has an analysts' consensus of $2.53 which suggests that it could grow by 357.18%. Given that Accuray, Inc. has higher upside potential than InMode Ltd., analysts believe Accuray, Inc. is more attractive than InMode Ltd..

InMode Ltd. has a beta of 2.187, which suggesting that the stock is 118.719% more volatile than S&P 500. In comparison Accuray, Inc. has a beta of 1.151, suggesting its more volatile than the S&P 500 by 15.124%.

InMode Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accuray, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InMode Ltd. pays -- of its earnings as a dividend. Accuray, Inc. pays out -- of its earnings as a dividend.

InMode Ltd. quarterly revenues are $103.9M, which are larger than Accuray, Inc. quarterly revenues of $102.2M. InMode Ltd.'s net income of $27M is higher than Accuray, Inc.'s net income of -$13.8M. Notably, InMode Ltd.'s price-to-earnings ratio is 10.44x while Accuray, Inc.'s PE ratio is 149.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InMode Ltd. is 2.66x versus 0.14x for Accuray, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Alphatec Holdings, Inc. has a net margin of 26.02% compared to InMode Ltd.'s net margin of -14.54%. InMode Ltd.'s return on equity of 14.27% beat Alphatec Holdings, Inc.'s return on equity of -1495.13%.

InMode Ltd. has a consensus price target of $16.80, signalling upside risk potential of 11.3%. On the other hand Alphatec Holdings, Inc. has an analysts' consensus of $24.62 which suggests that it could grow by 82.61%. Given that Alphatec Holdings, Inc. has higher upside potential than InMode Ltd., analysts believe Alphatec Holdings, Inc. is more attractive than InMode Ltd..

InMode Ltd. has a beta of 2.187, which suggesting that the stock is 118.719% more volatile than S&P 500. In comparison Alphatec Holdings, Inc. has a beta of 1.013, suggesting its more volatile than the S&P 500 by 1.34%.

InMode Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alphatec Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InMode Ltd. pays -- of its earnings as a dividend. Alphatec Holdings, Inc. pays out -- of its earnings as a dividend.

InMode Ltd. quarterly revenues are $103.9M, which are smaller than Alphatec Holdings, Inc. quarterly revenues of $196.5M. InMode Ltd.'s net income of $27M is higher than Alphatec Holdings, Inc.'s net income of -$28.6M. Notably, InMode Ltd.'s price-to-earnings ratio is 10.44x while Alphatec Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InMode Ltd. is 2.66x versus 2.74x for Alphatec Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific Corp. has a net margin of 26.02% compared to InMode Ltd.'s net margin of 12.68%. InMode Ltd.'s return on equity of 14.27% beat Boston Scientific Corp.'s return on equity of 12.55%.

InMode Ltd. has a consensus price target of $16.80, signalling upside risk potential of 11.3%. On the other hand Boston Scientific Corp. has an analysts' consensus of $104.75 which suggests that it could grow by 38.34%. Given that Boston Scientific Corp. has higher upside potential than InMode Ltd., analysts believe Boston Scientific Corp. is more attractive than InMode Ltd..

InMode Ltd. has a beta of 2.187, which suggesting that the stock is 118.719% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.441%.

InMode Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InMode Ltd. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

InMode Ltd. quarterly revenues are $103.9M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. InMode Ltd.'s net income of $27M is lower than Boston Scientific Corp.'s net income of $670M. Notably, InMode Ltd.'s price-to-earnings ratio is 10.44x while Boston Scientific Corp.'s PE ratio is 39.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InMode Ltd. is 2.66x versus 5.64x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of 26.02% compared to InMode Ltd.'s net margin of -316.61%. InMode Ltd.'s return on equity of 14.27% beat Plus Therapeutics, Inc.'s return on equity of --.

InMode Ltd. has a consensus price target of $16.80, signalling upside risk potential of 11.3%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1778.42%. Given that Plus Therapeutics, Inc. has higher upside potential than InMode Ltd., analysts believe Plus Therapeutics, Inc. is more attractive than InMode Ltd..

InMode Ltd. has a beta of 2.187, which suggesting that the stock is 118.719% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

InMode Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InMode Ltd. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

InMode Ltd. quarterly revenues are $103.9M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. InMode Ltd.'s net income of $27M is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, InMode Ltd.'s price-to-earnings ratio is 10.44x while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InMode Ltd. is 2.66x versus 4.69x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.